PARP inhibitors: Synthetic lethality in the clinic
暂无分享,去创建一个
[1] J. Garber,et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale , 2016, Future oncology.
[2] M. Salto‐Tellez,et al. Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer , 2016, Journal of the National Cancer Institute.
[3] Antonio González Martín. Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer , 2017 .
[4] Anne Floquet,et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[5] U. Rix,et al. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. , 2016, Cell chemical biology.
[6] A. Ashworth,et al. PARP inhibitor combination therapy. , 2016, Critical reviews in oncology/hematology.
[7] D. Matei,et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. , 2016, The Lancet. Oncology.
[8] Y. Pommier,et al. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action , 2016, Science Translational Medicine.
[9] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[10] G. Mills,et al. A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation , 2016 .
[11] C. Lord,et al. Synthetic lethality: the road to novel therapies for breast cancer. , 2016, Endocrine-related cancer.
[12] S. Cantor,et al. Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells , 2016, Nature.
[13] Jonathan H. Young,et al. Predictability of Genetic Interactions from Functional Gene Modules , 2016, G3: Genes, Genomes, Genetics.
[14] E. Kohn,et al. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer , 2016, Expert opinion on investigational drugs.
[15] Z. Szallasi,et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.
[16] Bissan Al-Lazikani,et al. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines , 2016, Cell reports.
[17] J. Pascal,et al. Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1 , 2015, Molecular cell.
[18] Jamin D Steffen,et al. PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain. , 2015, Molecular cell.
[19] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[20] M. Morgan,et al. 2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation , 2015 .
[21] Michael S. Goldberg,et al. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. , 2015, Biochemical and biophysical research communications.
[22] Liang Zhao,et al. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.
[23] P. Gimotty,et al. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer , 2015, Cancer Immunology Research.
[24] Peter Bouwman,et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition , 2015, Nature.
[25] A. Ashworth,et al. Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[27] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] E. Kohn,et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. , 2014, The Lancet. Oncology.
[29] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[30] M. King. “The Race” to Clone BRCA1 , 2014, Science.
[31] Y. Pommier,et al. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.
[32] Johann S. de Bono,et al. Appraising iniparib, the PARP inhibitor that never was—what must we learn? , 2013, Nature Reviews Clinical Oncology.
[33] Alan Ashworth,et al. Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.
[34] A. Ashworth,et al. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency , 2013, Clinical Cancer Research.
[35] A. Ashworth,et al. A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity , 2013, PloS one.
[36] N. Curtin,et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation , 2013, Cancer Chemotherapy and Pharmacology.
[37] A. Ashworth,et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor , 2013, The Journal of pathology.
[38] Shridar Ganesan,et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.
[39] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[40] Lei He,et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.
[41] V. Schreiber,et al. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. , 2012, Biochemical pharmacology.
[42] D. Matei,et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.
[43] H. Mackay,et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.
[44] Rochelle L. Garcia,et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[46] A. Ashworth,et al. Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.
[47] A. Ashworth,et al. A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.
[48] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[49] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[50] W. Kraus,et al. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. , 2010, Molecular cell.
[51] Jan Lubinski,et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Y. Drew,et al. Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors , 2010, Clinical Cancer Research.
[53] M. Jasin,et al. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis , 2010, Nature Reviews Molecular Cell Biology.
[54] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[55] Jorge S. Reis-Filho,et al. Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.
[56] F. Couch,et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.
[57] N. Curtin,et al. PARP inhibitor development for systemic cancer targeting. , 2007, Anti-cancer agents in medicinal chemistry.
[58] Alan Ashworth,et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.
[59] A. Tong,et al. Synthetic genetic array analysis in Saccharomyces cerevisiae. , 2006, Methods in molecular biology.
[60] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[61] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[62] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[63] A. Ashworth,et al. Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences , 2001, The EMBO journal.
[64] M. Jasin,et al. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. , 2001, Cancer research.
[65] M. Jasin,et al. BRCA2 is required for homology-directed repair of chromosomal breaks. , 2001, Molecular cell.
[66] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[67] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[68] Masahiko S. Satoh,et al. Role of poly(ADP-ribose) formation in DNA repair , 1992, Nature.
[69] M. R. Purnell,et al. Novel inhibitors of poly(ADP-ribose) synthetase. , 1980, The Biochemical journal.
[70] P. Marks,et al. Induction of erythroid differentiation of murine erythroleukemia cells by nicotinamide and related compounds. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[71] T. Sugimura,et al. Seminar on Poly(ADP-Ribose) and ADP-ribosylation of Protine , 1975 .
[72] S. Shall. Proceedings: Experimental manipulation of the specific activity of poly(ADP-ribose) polymerase. , 1975, Journal of biochemistry.